Stephen Slocum
Director - Drug Development, Project Lead LigaChem Biosciences
Seminars
Wednesday 14th October 2026
Reviewing Case Studies to Understand How ADC Design Influences Early-Stage Clinical Outcomes
11:00 am
- Evaluating opportunities for ADCs with novel design to deliver differentiated clinical outcomes
- Reviewing early-stage clinical results from LCB14 to understand the impact of bioconjugation and linker within the HER2 targeting ADC space
- Delving into the early clinical profile of LCB71, a pro-PBD bearing ROR1 targeting ADC, demonstrating differentiated clinical safety and efficacy
Tuesday 13th October 2026
Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation
11:30 am
- Discussing how site specific ConjuAll platform enables discrete DAR ADCs with circulation stable bioconjugation
- Leveraging proprietary beta glucuronidase technology to enable unprecedented preclinical therapeutic indexes through tumor selective release and payload activation
- Assessing early clinical safety and efficacy across payload classes to validate the LCB platform
